Your browser doesn't support javascript.
loading
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.
Tobin, Richard P; Cogswell, Dasha T; Cates, Victoria M; Davis, Dana M; Borgers, Jessica S W; Van Gulick, Robert J; Katsnelson, Elizabeth; Couts, Kasey L; Jordan, Kimberly R; Gao, Dexiang; Davila, Eduardo; Medina, Theresa M; Lewis, Karl D; Gonzalez, Rene; McFarland, Ross W; Robinson, William A; McCarter, Martin D.
Affiliation
  • Tobin RP; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Cogswell DT; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Cates VM; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Davis DM; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Borgers JSW; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Van Gulick RJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Katsnelson E; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Couts KL; Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Jordan KR; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Gao D; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Davila E; Department of Pediatrics, Biostatistics, and Informatics, Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Medina TM; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Lewis KD; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Gonzalez R; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • McFarland RW; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Robinson WA; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • McCarter MD; UCHealth Cancer Care and Hematology Clinic-Harmony Campus, Fort Collins, Colorado.
Clin Cancer Res ; 29(7): 1209-1219, 2023 04 03.
Article in En | MEDLINE | ID: mdl-36378549
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Second Primary / Myeloid-Derived Suppressor Cells / Melanoma Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms, Second Primary / Myeloid-Derived Suppressor Cells / Melanoma Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: Estados Unidos